$1.09
-0.13 (-10.66%)
Open$1.25
Previous Close$1.22
Day High$1.27
Day Low$1.08
52W High$4.70
52W Low$1.11
Volume—
Avg Volume299.0K
Market Cap15.60M
P/E Ratio—
EPS$-1.61
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,283.5% upside
Current
$1.09
$1.09
Target
$25.98
$25.98
$20.93
$25.98 avg
$39.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.75M | 4.21M | 3.91M |
| Net Income | 909.1K | 778.9K | 578.2K |
| Profit Margin | 19.1% | 18.5% | 14.8% |
| EBITDA | 1.38M | 1.12M | 1.11M |
| Free Cash Flow | 932.9K | 1.05M | 869.6K |
| Rev Growth | +21.8% | +17.5% | +9.1% |
| Debt/Equity | 0.24 | 0.30 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |